Embecta (NASDAQ:EMBC) Sets New 1-Year Low - Should You Sell?

Shares of Embecta Corp. (NASDAQ:EMBC - Get Free Report) reached a new 52-week low during trading on Monday . The company traded as low as $9.49 and last traded at $9.73, with a volume of 50893 shares traded. The stock had previously closed at $9.56.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on EMBC. BTIG Research set a $25.00 price target on Embecta and gave the company a "buy" rating in a research note on Friday, May 23rd. Wall Street Zen upgraded Embecta from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. Finally, Mizuho reduced their price objective on shares of Embecta from $15.00 to $13.00 and set a "neutral" rating for the company in a research note on Friday, May 23rd.

Embecta Trading Up 4.3%

The firm has a market cap of $582.68 million, a price-to-earnings ratio of 9.96, a PEG ratio of 0.78 and a beta of 1.13. The firm has a 50-day moving average of $11.45 and a two-hundred day moving average of $15.00.

Embecta (NASDAQ:EMBC - Get Free Report) last announced its quarterly earnings data on Friday, May 9th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.66 by $0.04. The business had revenue of $259.00 million for the quarter, compared to the consensus estimate of $261.77 million. Embecta had a net margin of 5.25% and a negative return on equity of 19.22%. Embecta's quarterly revenue was down 9.8% on a year-over-year basis. During the same quarter last year, the company posted $0.67 earnings per share. As a group, equities analysts anticipate that Embecta Corp. will post 2.85 EPS for the current year.

Embecta Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, June 13th. Stockholders of record on Wednesday, May 28th were paid a dividend of $0.15 per share. The ex-dividend date of this dividend was Wednesday, May 28th. This represents a $0.60 annualized dividend and a dividend yield of 6.02%. Embecta's dividend payout ratio (DPR) is currently 66.67%.

Insider Buying and Selling at Embecta

In other Embecta news, Director David F. Melcher purchased 10,000 shares of the stock in a transaction on Friday, May 23rd. The stock was bought at an average cost of $10.60 per share, for a total transaction of $106,000.00. Following the completion of the acquisition, the director now directly owns 86,681 shares of the company's stock, valued at $918,818.60. The trade was a 13.04% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.42% of the company's stock.

Institutional Investors Weigh In On Embecta

Several hedge funds have recently added to or reduced their stakes in the business. William Blair Investment Management LLC bought a new stake in Embecta in the 4th quarter valued at about $15,270,000. American Century Companies Inc. increased its position in shares of Embecta by 16.9% in the first quarter. American Century Companies Inc. now owns 3,813,411 shares of the company's stock worth $48,621,000 after purchasing an additional 551,477 shares during the period. Deerfield Management Company L.P. Series C raised its stake in Embecta by 19.8% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 3,270,535 shares of the company's stock valued at $67,537,000 after purchasing an additional 540,192 shares in the last quarter. Raymond James Financial Inc. acquired a new position in Embecta in the fourth quarter valued at about $6,598,000. Finally, Jefferies Financial Group Inc. increased its stake in Embecta by 60.1% in the first quarter. Jefferies Financial Group Inc. now owns 573,000 shares of the company's stock valued at $7,306,000 after acquiring an additional 215,000 shares during the last quarter. Institutional investors and hedge funds own 93.83% of the company's stock.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.